
Disease Modification in Urticaria
All Things Urticaria – Learning about urticaria with Prof. Dr. Torsten ZuberbierShow Notes
In this episode of the UCARE Global Allergy and Asthma Excellence Network (Global Allergy and Asthma Excellence Network) podcast on Urticaria, Prof. Torsten Zuberbier speaks with Prof. Akio Tanaka from Hiroshima University, Japan, about an important question many patients ask: how long will chronic urticaria last, and can treatment influence the course of the disease? They discuss disease modification, symptom control, and future research directions in urticaria management.
They discuss: 🔹 How long does chronic spontaneous urticaria typically last? 🔹 Can early and effective treatment shorten disease duration? 🔹 Why is complete symptom control an important treatment goal? 🔹 What role do antihistamines, omalizumab, dupilumab, and remibrutinib play in long-term management? 🔹 Could food-related pseudoallergic reactions contribute to persistent symptoms? 🔹 What might the gut microbiome teach us about urticaria in the future? 🔹 How can international collaboration help answer these unanswered questions?
The discussion explores the possibility that optimal disease control may do more than relieve symptoms—it may also influence the overall course of urticaria. The episode highlights emerging ideas around disease modification, dietary influences, and the microbiome, while emphasizing the need for future research.
Key Learnings from the Episode: Chronic spontaneous urticaria is usually a temporary disease, not a lifelong condition. Many patients achieve remission, although it may take several years. Complete symptom control should be a key treatment goal. Early and effective treatment may potentially shorten disease duration. Antihistamines remain an important foundation of treatment. Add-on therapies such as omalizumab, dupilumab, and remibrutinib expand treatment options. Food-related pseudoallergic reactions may contribute to symptoms in some patients. The gut microbiome may play a role in urticaria and warrants further research. Patient education and reassurance are important parts of care. International research networks such as UCARE help advance knowledge and improve outcomes.
Chapters 00:00 Introduction of Experts and Topic Overview 01:04 Patient Questions About Disease Duration 02:08 Statistics on Long-Term Urticaria and Hopeful Messaging 04:23 Disease Modification and Early Treatment Strategies 06:24 Impact of Symptom Control on Disease Duration 08:29 Guidelines for Treatment Escalation and New Therapies 10:01 Combination Therapy and Disease Management Goals 12:07 Role of Food, Pseudoallergy, and Microbiome in Urticaria 14:18 Research on Microbiome and Traditional Diets 16:29 Closing Remarks and Future Directions
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Feedback form: ATU: https://forms.office.com/e/m6a2uEdsUH
More from All Things Urticaria – Learning about urticaria with Prof. Dr. Torsten Zuberbier
In this episode of the UCARE Global Allergy and Asthma Excellence Network podcast on Urticaria, Prof. Torsten Zuberbier speaks with Prof. Angelo Valerio Marzano from Milan about urticarial vasculitis and its challenging differential diagnoses. They explore how clinicians can distinguish urticarial vasculitis from chronic urticaria and other dermatological or systemic conditions and discuss practical approaches to diagnosis and treatment.
In this episode of the Global Allergy and Asthma Excellence Network UCARE Podcast on Urticaria, Prof. Torsten Zuberbier speaks with Prof. Marta Ferrer from Spain about an important question: Is chronic spontaneous urticaria (CSU) only a skin disease, or is it a systemic inflammatory condition? Together, they discuss emerging evidence showing that urticaria affects far more than the skin and how this should influence patient management.
In this episode of the UCARE GA²LEN (Global Allergy and Asthma Excellence Network) podcast on Urticaria, Prof. Torsten Zuberbier and Prof. Hermenio Lima discuss the growing role of artificial intelligence (AI) in medicine and how it may influence urticaria care, research, and patient management in the future.
In this episode of the UCARE GA²LEN (Global Allergy and Asthma Excellence Network) podcast on Urticaria, Prof. Torsten Zuberbier and Prof. Maia Gotua discuss the role of infections in acute and chronic urticaria. They explore how infections can trigger, mimic, or worsen symptoms—and why careful clinical evaluation is key.
In this episode of “All Things Urticaria” — a podcast from UCARE, the Global Allergy and Asthma Excellence Network — Prof. Torsten Zuberbier and Prof. Ana Giménez-Arnau discuss the newly released international urticaria guidelines. Developed with contributions from more than 100 societies and hundreds of experts worldwide, these guidelines represent a major step forward in the management of chronic spontaneous urticaria (CSU).